1. Home
  2. HOWL vs CTMX Comparison

HOWL vs CTMX Comparison

Compare HOWL & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HOWL
  • CTMX
  • Stock Information
  • Founded
  • HOWL 2017
  • CTMX 2008
  • Country
  • HOWL United States
  • CTMX United States
  • Employees
  • HOWL N/A
  • CTMX N/A
  • Industry
  • HOWL Biotechnology: Pharmaceutical Preparations
  • CTMX Biotechnology: Pharmaceutical Preparations
  • Sector
  • HOWL Health Care
  • CTMX Health Care
  • Exchange
  • HOWL Nasdaq
  • CTMX Nasdaq
  • Market Cap
  • HOWL 87.4M
  • CTMX 62.3M
  • IPO Year
  • HOWL 2021
  • CTMX 2015
  • Fundamental
  • Price
  • HOWL $1.49
  • CTMX $0.80
  • Analyst Decision
  • HOWL Strong Buy
  • CTMX Buy
  • Analyst Count
  • HOWL 2
  • CTMX 6
  • Target Price
  • HOWL $9.50
  • CTMX $5.77
  • AVG Volume (30 Days)
  • HOWL 260.9K
  • CTMX 731.5K
  • Earning Date
  • HOWL 03-06-2025
  • CTMX 03-10-2025
  • Dividend Yield
  • HOWL N/A
  • CTMX N/A
  • EPS Growth
  • HOWL N/A
  • CTMX N/A
  • EPS
  • HOWL N/A
  • CTMX 0.16
  • Revenue
  • HOWL $3,386,000.00
  • CTMX $126,617,000.00
  • Revenue This Year
  • HOWL N/A
  • CTMX $22.55
  • Revenue Next Year
  • HOWL $34.17
  • CTMX N/A
  • P/E Ratio
  • HOWL N/A
  • CTMX $4.93
  • Revenue Growth
  • HOWL N/A
  • CTMX 33.66
  • 52 Week Low
  • HOWL $1.26
  • CTMX $0.75
  • 52 Week High
  • HOWL $8.19
  • CTMX $5.85
  • Technical
  • Relative Strength Index (RSI)
  • HOWL 54.09
  • CTMX 41.61
  • Support Level
  • HOWL $1.28
  • CTMX $0.75
  • Resistance Level
  • HOWL $1.60
  • CTMX $0.98
  • Average True Range (ATR)
  • HOWL 0.10
  • CTMX 0.06
  • MACD
  • HOWL 0.03
  • CTMX 0.00
  • Stochastic Oscillator
  • HOWL 67.65
  • CTMX 20.13

About HOWL Werewolf Therapeutics Inc.

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: